10-QPeriod: Q1 FY2017

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2017

Filed April 28, 2017For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported a strong first quarter for 2017, demonstrating robust revenue growth and improved profitability. Total revenue increased by 10.7% to $462.0 million, driven by a significant 12.7% rise in the Companion Animal Group (CAG) segment. This growth was fueled by strong performance in recurring diagnostic revenue, consumables, and instrument placements. The company also saw healthy growth in its Water segment, although the Livestock, Poultry and Dairy (LPD) segment experienced a slight decline. Profitability improved significantly, with Income from Operations up 25.0% to $92.2 million. This was supported by an expansion in gross profit margin and effective management of operating expenses. Notably, the company's effective income tax rate decreased substantially from 30.6% in Q1 2016 to 18.5% in Q1 2017, largely due to the adoption of new accounting guidance for share-based compensation. Earnings per share also saw a substantial increase, with diluted EPS rising to $0.77 from $0.51 in the prior year. Financially, IDEXX maintained a solid liquidity position with $400.3 million in cash, cash equivalents, and marketable securities. The company continued its share repurchase program, reflecting a commitment to returning value to shareholders. Overall, the results indicate a healthy operational performance and positive financial momentum for IDEXX Laboratories in early 2017.

Financial Highlights

52 data points
Beta

Revenue

$462.02M

55.9% Gross Margin

Net Income

$69.02M

14.9% Net Margin

EPS (Diluted)

$0.77

Total Assets

$1.57B

Cash & Equivalents

$160.41M

Free Cash Flow

$7.63M

Financial Statements
Beta
Revenue$462.02M
Cost of Revenue$203.83M
Gross Profit$258.19M
R&D Expenses$25.79M
Operating Income$92.24M
Interest Expense$8.59M
Net Income$69.02M
EPS (Basic)$0.78
EPS (Diluted)$0.77
Shares Outstanding (Basic)88.12M
Shares Outstanding (Diluted)89.99M

Key Highlights

  • 1Total revenue increased by 10.7% year-over-year to $462.0 million.
  • 2Companion Animal Group (CAG) revenue grew by 12.7% to $403.2 million, driven by strong demand for diagnostic recurring revenue and consumables.
  • 3Income from operations surged by 25.0% to $92.2 million, indicating improved profitability.
  • 4Diluted Earnings Per Share (EPS) increased to $0.77 from $0.51 in the prior year's quarter.
  • 5Effective income tax rate decreased significantly from 30.6% to 18.5%, primarily due to the adoption of ASU 2016-09 related to share-based compensation.
  • 6The company maintained a healthy liquidity position with $400.3 million in cash, cash equivalents, and marketable securities.
  • 7Share repurchases continued, with $58.0 million spent in the quarter on buying back common stock.

Frequently Asked Questions

The primary driver of IDEXX's revenue growth was the strong performance of its Companion Animal Group (CAG) segment, which saw a 12.7% increase in revenue. This growth was primarily fueled by higher volumes in reference laboratory diagnostic services, IDEXX VetLab consumables, and increased placements of diagnostic capital instruments like the SediVue Dx analyzer.

The adoption of ASU 2016-09 concerning share-based compensation had a significant impact, primarily by reducing the effective income tax rate from 30.6% in Q1 2016 to 18.5% in Q1 2017. This tax benefit contributed substantially to the reported net income and earnings per share. Additionally, it affected the classification of certain cash flows, moving tax benefits related to share-based payments from financing to operating activities.

IDEXX Laboratories maintained a strong liquidity position with $400.3 million in cash, cash equivalents, and marketable securities at the end of the first quarter of 2017. The company also had $178.0 million in remaining borrowing availability under its credit facility. This financial strength, combined with funds generated from operations, is deemed sufficient to fund operations and anticipated growth needs for the next twelve months and beyond.

While the Companion Animal Group and Water segments showed growth, the Livestock, Poultry and Dairy (LPD) segment experienced a 5.0% decline in revenue. This decrease was mainly attributed to lower herd health screening in the Asia-Pacific region and reduced dairy testing volumes in China and Brazil. The 'Other' segment, which includes OPTI Medical, also saw a significant revenue decrease of 20.0% due to temporary product availability constraints.